Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Focus on HDL as a therapeutic target for CAD risk reduction.

Focus on HDL as a therapeutic target for CAD risk reduction. Am J Cardiol. 2009 Nov 16; 104(10 Suppl):1E-2E.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.